Analysis of natural product regulation of opioid receptors in the treatment of human disease DOI
Simone Badal, Sophie C. Turfus, Rajendram V. Rajnarayanan

и другие.

Pharmacology & Therapeutics, Год журнала: 2017, Номер 184, С. 51 - 80

Опубликована: Окт. 31, 2017

Язык: Английский

Meta-review on the efficacy of psychological therapies for the treatment of substance use disorders DOI
Laura Dellazizzo, Stéphane Potvin, Sabrina Giguère

и другие.

Psychiatry Research, Год журнала: 2023, Номер 326, С. 115318 - 115318

Опубликована: Июнь 19, 2023

Язык: Английский

Процитировано

23

Patients Who Have Cannabis Use Disorder Have Higher Rates of Venous Thromboemboli, Readmission Rates, and Costs Following Primary Total Knee Arthroplasty DOI
Rushabh M. Vakharia, Nipun Sodhi, Hiba K. Anis

и другие.

The Journal of Arthroplasty, Год журнала: 2019, Номер 35(4), С. 997 - 1002

Опубликована: Ноя. 28, 2019

Язык: Английский

Процитировано

48

Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings DOI
Andrew J. Kesner, David M. Lovinger

Journal of Neurochemistry, Год журнала: 2021, Номер 157(5), С. 1674 - 1696

Опубликована: Апрель 23, 2021

Abstract Cannabis sativa is the most widely used illicit drug in world. Its main psychoactive component delta‐9‐tetrahydrocannabinol (THC), one of over 100 phytocannabinoid compounds produced by cannabis plant. THC primary compound that drives abuse potential and also prescribed medically for therapeutic qualities. Despite its potential, a significant subpopulation frequent or users will develop use syndrome termed disorder. Individuals suffering from disorder exhibit many hallmarks classical addictions including cravings, tolerance, withdrawal symptoms. Currently, there are no efficacious treatments This makes both clinical preclinical research on neurobiological mechanisms these syndromes ever more pertinent. Indeed, basic using animal models has provided valuable evidence neural molecular cellular actions mediate behavioral effects. One components being central action cannabinoid type‐one receptor downstream intracellular signaling related to endogenous system. Back‐translational studies have insight linking biology better understand symptoms observed at level. narrative review aims summarize major elucidating molecular, cellular, manifestations cannabis/THC play role withdrawal. image

Язык: Английский

Процитировано

39

Synaptic changes induced by cannabinoid drugs and cannabis use disorder DOI Creative Commons
Shana M. Augustin, David M. Lovinger

Neurobiology of Disease, Год журнала: 2022, Номер 167, С. 105670 - 105670

Опубликована: Фев. 24, 2022

Язык: Английский

Процитировано

27

What Obstetrician–Gynecologists Should Know About Substance Use Disorders in the Perinatal Period DOI
Marcela C. Smid, Mishka Terplan

Obstetrics and Gynecology, Год журнала: 2022, Номер unknown

Опубликована: Янв. 6, 2022

Substance use in pregnancy is common; nearly one of five pregnant individuals have past-month nicotine, alcohol, or illicit substance use, and more than 10 meet criteria for a disorder (SUD). disorders are among the most stigmatized poorly understood medical conditions, particularly perinatal period. The obstetrician-gynecologist (ob-gyn) critical member health care social support team postpartum with SUD. Yet, many do not feel knowledgeable screening treating SUD, hampering efforts to identify treat this population. In review, we focus on practices that ob-gyns can incorporate into daily care. We start unique vulnerabilities period discuss overdose as leading cause maternal death United States. then review basic tenets addiction medicine including person-centered language current terminology well best screening. provide maternal, fetal, child effects common substances tobacco, cannabis, opioids, stimulants, benzodiazepines their respective treatment recommendations, so management practice.

Язык: Английский

Процитировано

27

Validity of the Single-Item Screen–Cannabis (SIS-C) for Cannabis Use Disorder Screening in Routine Care DOI Creative Commons
Theresa E. Matson, Gwen T. Lapham, Jennifer F. Bobb

и другие.

JAMA Network Open, Год журнала: 2022, Номер 5(11), С. e2239772 - e2239772

Опубликована: Ноя. 1, 2022

Importance Cannabis use is prevalent and increasing, frequent intensifies the risk of cannabis disorder (CUD). CUD underrecognized in medical settings, but a validated single-item screen could increase recognition. Objective To evaluate Single-Item Screen–Cannabis (SIS-C), administered documented routine primary care, compared with confidential reference standard measure CUD. Design, Setting, Participants This diagnostic study included sample adult patients who completed screening between January 28 September 12, 2019, were randomly selected for survey about use. Random sampling was stratified by frequency past-year race ethnicity. The conducted at an integrated health system Washington state, where legal. Data analyzed from May 2021 to March 2022. Exposures SIS-C asks responses (none, less than monthly, weekly, daily or almost daily) patients’ records. Main Outcomes Measures Diagnostic Statistical Manual , Fifth Edition ( DSM-5 ) Composite International Interview–Substance Abuse Module (CIDI-SAM) on considered standard. 2 more criteria CIDI-SAM, consistent All analyses weighted, accounting design nonresponse, obtain estimates representative care population. Results Of 5000 sampled patients, 1688 responded (34% response rate). Patients predominantly middle-aged (weighted mean [SD] age, 50.7 [18.1]), female women proportion [SE], 55.9% [4.1]), non-Hispanic 96.7% [1.0]), White 74.2% [3.7]). Approximately 6.6% met had area under receiver operating characteristic curve 0.89 (95% CI, 0.78-0.96) identifying A threshold monthly balanced sensitivity (0.88) specificity (0.83) detecting In populations 6% prevalence CUD, predictive values positive ranged 17% 34%, while negative 97% 100%. Conclusions Relevance this study, excellent performance characteristics as While high suggest that accurately identifies without low indicate need further assessment following results when care.

Язык: Английский

Процитировано

24

Substance Use Disorders in the Geriatric Population: a Review and Synthesis of the Literature of a Growing Problem in a Growing Population DOI Open Access
Jenny Lin, Mitchell Arnovitz,

Nabil Kotbi

и другие.

Current Treatment Options in Psychiatry, Год журнала: 2023, Номер 10(3), С. 313 - 332

Опубликована: Июнь 5, 2023

Язык: Английский

Процитировано

16

Cannabis Legalization and the Decline of Cannabis Use Disorder (CUD) Treatment Utilization in the US DOI
Jeremy Mennis, Gerald J. Stahler, Michael J. Mason

и другие.

Current Addiction Reports, Год журнала: 2023, Номер 10(1), С. 38 - 51

Опубликована: Янв. 10, 2023

Язык: Английский

Процитировано

15

Psychometric Performance of a Substance Use Symptom Checklist to Help Clinicians Assess Substance Use Disorder in Primary Care DOI Creative Commons
Theresa E. Matson, Kevin A. Hallgren, Gwen T. Lapham

и другие.

JAMA Network Open, Год журнала: 2023, Номер 6(5), С. e2316283 - e2316283

Опубликована: Май 26, 2023

Substance use disorders (SUDs) are underrecognized in primary care, where structured clinical interviews often infeasible. A brief, standardized substance symptom checklist could help clinicians assess SUD.To evaluate the psychometric properties of Use Symptom Checklist (hereafter checklist) used care among patients reporting daily cannabis and/or other drug as part population-based screening and assessment.This cross-sectional study was conducted adult who completed during routine between March 1, 2015, 2020, at an integrated health system. Data analysis from June 2021, to May 2022.The included 11 items corresponding SUD criteria Diagnostic Statistical Manual for Mental Disorders (Fifth Edition) (DSM-5). Item response theory (IRT) analyses tested whether unidimensional reflected a continuum severity evaluated item characteristics (discrimination severity). Differential functioning examined performed similarly across age, sex, race, ethnicity. Analyses were stratified by use.A total 23 304 screens (mean [SD] 38.2 [5.6] years; 12 554 [53.9%] male patients; 17 439 [78.8%] White 20 393 [87.5%] non-Hispanic patients). Overall, 16 140 reported only, 4791 2373 both use. Among with or use, 4242 (26.3%), 1446 (30.2%), 1229 (51.8%), respectively, endorsed 2 more on checklist, consistent DSM-5 SUD. For all subsamples, IRT models supported unidimensionality discriminated higher lower levels severity. observed some sociodemographic subgroups but did not result meaningful change (<1 point difference) overall score (0-11).In this study, administered screening, expected well subgroups. Findings support utility complete assessment make diagnostic treatment decisions care.

Язык: Английский

Процитировано

14

Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder DOI
Dustin C. Lee, Nicolas J. Schlienz, Erica N. Peters

и другие.

Drug and Alcohol Dependence, Год журнала: 2018, Номер 194, С. 500 - 517

Опубликована: Ноя. 15, 2018

Язык: Английский

Процитировано

43